Due to delivery obstacles, Simvastatin, a potential anticancer agent, faces clinical limitations.
This study aimed to enhance simvastatin delivery and efficacy against triple-negative breast cancer (TNBC) by developing liposomes modified with sodium oleate (NaOL) to improve endosomal escape.
